Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE-2 episodic migraine prevention study
NL-OMON45766Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of galcanezumab in episodic migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall mean change from baseline in monthly migraine headache days. Started Feb 2016; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NL-OMON45766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45766.